Efficacy and safety of sitagliptin monotherapy and combination therapy in Japanese type 2 diabetes patients (Q33587806)

28 July 2017

Efficacy and safety of sitagliptin monotherapy and combination therapy in Japanese type 2 diabetes patients (English)

1 reference

28 July 2017

0 references

Akira Kubota

1

1 reference

28 July 2017

Hajime Maeda

2

1 reference

28 July 2017

Akira Kanamori

3

1 reference

28 July 2017

Kiyokazu Matoba

4

1 reference

28 July 2017

Yasuyuki Jin

5

1 reference

28 July 2017

Fuyuki Minagawa

6

1 reference

28 July 2017

Mitsuo Obana

7

1 reference

28 July 2017

Kotaro Iemitsu

8

1 reference

28 July 2017

Shogo Ito

9

1 reference

28 July 2017

Hikaru Amamiya

10

1 reference

28 July 2017

Mizuki Kaneshiro

11

1 reference

28 July 2017

Masahiko Takai

12

1 reference

28 July 2017

Hideaki Kaneshige

13

1 reference

28 July 2017

Kazuhiko Hoshino

14

1 reference

28 July 2017

Masashi Ishikawa

15

1 reference

28 July 2017

Nobuaki Minami

16

1 reference

28 July 2017

Tetsuro Takuma

17

1 reference

28 July 2017

Nobuo Sasai

18

1 reference

28 July 2017

Sachio Aoyagi

19

1 reference

28 July 2017

Takehiro Kawata

20

1 reference

28 July 2017

Atsuko Mokubo

21

1 reference

28 July 2017

Hiroshi Takeda

22

1 reference

28 July 2017

Shin Honda

23

1 reference

28 July 2017

Hideo Machimura

24

1 reference

28 July 2017

Tetsuya Motomiya

25

1 reference

28 July 2017

Manabu Waseda

26

1 reference

28 July 2017

Yoshikazu Naka

27

1 reference

28 July 2017

Yasushi Tanaka

28

1 reference

28 July 2017

Yasuo Terauchi

29

1 reference

28 July 2017

Ikuro Matsuba

30

1 reference

28 July 2017

1 December 2012

1 reference

Journal of Diabetes Investigation

28 July 2017

1 reference

28 July 2017

3

1 reference

28 July 2017

503-509

1 reference

28 July 2017

6

1 reference

Cross-sectional survey of diabetic neuropathy in Kanagawa and clinical significance of a touch test using tissue paper

28 July 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4015429

Effects of glucose and meal ingestion on incretin secretion in Japanese subjects with normal glucose tolerance

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4015429

Secretory units of islets in transplantation index is a useful clinical marker to evaluate the efficacy of sitagliptin in treatment of type 2 diabetes mellitus

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4015429

Plasma gastric inhibitory polypeptide and glucagon-like peptide-1 levels after glucose loading are associated with different factors in Japanese subjects

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4015429

Report of the committee on the classification and diagnostic criteria of diabetes mellitus

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4015429

Little enhancement of meal-induced glucagon-like peptide 1 secretion in Japanese: Comparison of type 2 diabetes patients and healthy controls

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4015429

GIP and GLP-1, the two incretin hormones: Similarities and differences

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4015429

Exendin-4 suppresses SRC activation and reactive oxygen species production in diabetic Goto-Kakizaki rat islets in an Epac-dependent manner

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4015429

Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down?

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4015429

Present status of sulfonylurea treatment for type 2 diabetes in Japan: second report of a cross-sectional survey of 15,652 patients

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4015429

The cAMP sensor Epac2 is a direct target of antidiabetic sulfonylurea drugs

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4015429

Essential role of Epac2/Rap1 signaling in regulation of insulin granule dynamics by cAMP.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4015429

Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: focus on sitagliptin

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4015429

The place of sulfonylureas in the therapy for type 2 diabetes mellitus

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4015429

Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4015429

Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4015429

Gut peptides and type 2 diabetes mellitus treatment

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4015429

Glimepiride in type 2 diabetes mellitus: a review of the worldwide therapeutic experience

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4015429

Impaired beta-cell function and insulin sensitivity in Japanese subjects with normal glucose tolerance

21 June 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2040-1124.2012.00221.X

Insulin secretion and insulin sensitivity at different stages of glucose tolerance: a cross-sectional study of Japanese type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2040-1124.2012.00221.X

Heterogeneous relationship of early insulin response and fasting insulin level with development of non-insulin-dependent diabetes mellitus in non-diabetic Japanese subjects with or without obesity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2040-1124.2012.00221.X

Dose-ranging efficacy of sitagliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2040-1124.2012.00221.X

Efficacy and safety of sitagliptin monotherapy compared with voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2040-1124.2012.00221.X

Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2040-1124.2012.00221.X

Effect of Single Oral Doses of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, on Incretin and Plasma Glucose Levels after an Oral Glucose Tolerance Test in Patients with Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2040-1124.2012.00221.X

Dipeptidyl peptidase-4 inhibitors and HbA1c target of <7% in type 2 diabetes: meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.2040-1124.2012.00221.X

Contributing factors related to efficacy of the dipeptidyl peptidase-4 inhibitor sitagliptin in Japanese patients with type 2 diabetes

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24843615

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

GLP-I(7-36) amide augments Ba2+ current through L-type Ca2+ channel of rat pancreatic beta-cell in a cAMP-dependent manner

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24843615

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

The safety, efficacy and predictors for HbA1c reduction of sitagliptin in the treatment of Japanese type 2 diabetes

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24843615

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1111/J.2040-1124.2012.00221.X

1 reference

28 July 2017

1 reference

28 July 2017

1 reference